초록 ▼

The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of

The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

대표청구항 ▼

1. A self-supporting film dosage composition comprising: a. a dried polymeric carrier matrix;b. a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;c. a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; andd. a c

1. A self-supporting film dosage composition comprising: a. a dried polymeric carrier matrix;b. a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;c. a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; andd. a chelator;wherein the ratio of said naloxone or a pharmaceutically acceptable salt thereof to said chelator is from about 40:1 to about 1:10 by weight andwherein said chelator improves the stability of said naloxone or a pharmaceutically acceptable salt thereof. 2. The composition of claim 1, wherein said ratio of said naloxone or a pharmaceutically acceptable salt thereof to said chelator is from about 4:1 to about 1:10 by weight. 3. The composition of claim 1, wherein said ratio of said naloxone or a pharmaceutically acceptable salt thereof to said chelator is from about 5:1 to about 1:2 by weight. 4. The composition of claim 1, wherein said ratio of said naloxone or a pharmaceutically acceptable salt thereof to said chelator is from about 1:2 to about 2:1 by weight. 5. The composition of claim 1, wherein said chelator is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, proteins, polysaccharides, polynucleic acids, glutamic acid, histidine, organic diacids, polypeptides, phytochelatin, hemoglobin, chlorophyll, humic acid, phosphonates, transferrin, desferrioxamine, and combinations thereof. 6. The composition of claim 1, wherein said chelator is ethylenediaminetetraacetic acid disodium salt. 7. The composition of claim 1, further comprising a buffer in an amount sufficient to maximize the absorption of the buprenorphine or a pharmaceutically acceptable salt thereof. 8. The composition of claim 1, further comprising a buffering system comprising a buffer capacity sufficient to inhibit the absorption of said naloxone or a pharmaceutically acceptable salt thereof during the time which said composition is in the oral cavity of a user. 9. The composition of claim 1, wherein said composition comprises a first region and a second region, said first region comprising said buprenorphine or a pharmaceutically acceptable salt thereof and said second region comprising said naloxone or a pharmaceutically acceptable salt thereof and said chelator. 10. The composition of claim 1, wherein said buprenorphine or a pharmaceutically acceptable salt thereof has a local pH of about 3 to about 9. 11. The composition of claim 1, wherein said naloxone or a pharmaceutically acceptable salt thereof has a local pH of about 2 to about 4. 12. A self-supporting film dosage composition comprising: a. a dried polymeric carrier matrix;b. a therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;c. a therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; andd. ethylenediaminetetraacetic acid disodium salt (EDTA);wherein the ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is from about 5:1 to about 1:2 by weight andwherein said EDTA improves the stability of said naloxone or a pharmaceutically acceptable salt thereof. 13. The composition of claim 12, wherein said ratio of said naloxone or a pharmaceutically acceptable salt thereof to said EDTA is from about 1:2 to about 2:1 by weight. 14. The composition of claim 12, further comprising a buffer in an amount sufficient to maximize the absorption of the buprenorphine or a pharmaceutically acceptable salt thereof. 15. The composition of claim 12, further comprising a buffering system comprising a buffer capacity sufficient to inhibit the absorption of said naloxone or a pharmaceutically acceptable salt thereof during the time which said composition is in the oral cavity of a user. 16. The composition of claim 12, wherein said composition comprises a first region and a second region, said first region comprising said buprenorphine or a pharmaceutically acceptable salt thereof and said second region comprising said naloxone or a pharmaceutically acceptable salt thereof and said EDTA. 17. The composition of claim 12, wherein said buprenorphine or a pharmaceutically acceptable salt thereof has a local pH of about 3 to about 9. 18. The composition of claim 12, wherein said naloxone or a pharmaceutically acceptable salt thereof has a local pH of about 2 to about 4. 19. A self-supporting film dosage composition comprising: a. a dried polymeric carrier matrix;b. a therapeutically effective amount of buprenorphine hydrochloride;c. a therapeutically effective amount of naloxone hydrochloride;d. ethylenediaminetetraacetic acid disodium salt (EDTA); ande. citric acid;wherein the ratio of said naloxone hydrochloride to said EDTA is from about 4:1 to about 1:2 by weight andwherein said EDTA improves the stability of said naloxone hydrochloride. 20. The composition of claim 19, wherein said composition comprises a first region and a second region, said first region comprising said buprenorphine hydrochloride and said second region comprising said naloxone hydrochloride and said EDTA. 21. The composition of claim 1, further comprising an antioxidant. 22. The composition of claim 21, wherein said antioxidant is selected from the group consisting of dibutylhydroxytoluene (BHT), dibutylated hydroxyanisole (BHA), propyl gallate, sodium sulfate, citric acid, sodium metabisulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole, and combinations thereof. 23. The composition of claim 21, wherein said antioxidant is citric acid. 24. The composition of claim 12, further comprising an antioxidant. 25. The composition of claim 24, wherein said antioxidant is selected from the group consisting of dibutylhydroxytoluene (BHT), dibutylated hydroxyanisole (BHA), propyl gallate, sodium sulfate, citric acid, sodium metabisulfite, ascorbic acid, tocopherol, tocopherol ester derivatives, 2-mercaptobenzimidazole, and combinations thereof. 26. The composition of claim 24, wherein said antioxidant is citric acid.